Diagnostic and Prognostic Value of Plasma Adrenomedullin in COPD Exacerbation
Authors:
- 1 October 2014
- journal article
- Published by SAGE Publications in Respiratory Care
- Vol. 59 (10) , 1542-1549
Abstract
BACKGROUND: Adrenomedullin (ADM) is a regulatory peptide with many biological actions, but little is known about its role in patients with COPD exacerbation. The purpose of this study was to evaluate the diagnostic and prognostic value of plasma ADM levels on hospital admission in patients with COPD exacerbation. METHODS: Consecutive subjects admitted to the hospital for COPD exacerbation were included and were followed up for 1 y; in addition, subjects with stable COPD from an out-patient clinic and healthy volunteers were recruited as controls. RESULTS: Compared with healthy subjects (145 pg/mL [interquartile range {IQR} 103–290 pg/mL]), plasma ADM levels were significantly higher in subjects with COPD exacerbation (270 pg/mL [IQR 170–510 pg/mL], P = .001) and in subjects with stable COPD (400 pg/mL [IQR 210–525 pg/mL], P < .001). In subjects with COPD exacerbation, ADM levels were significantly elevated during exacerbation (560 pg/mL [IQR 495–630 pg/mL]) compared with the recovery phase (470 pg/mL [IQR 393–553 pg/mL], P = .01) and the stable phase (200 pg/mL [IQR 143–308 pg/mL], P < .001). In receiver operating characteristic analysis, in subjects with COPD exacerbation, ADM had high diagnostic accuracy in differentiating between exacerbation and the stable phase (area under the curve 0.97, 95% CI 0.93–1.02, P < .001). In Cox regression analysis, plasma ADM was not independently associated with 1-y survival ( P = .97), but it could accurately predicted the need for ICU care (hazard ratio 1.37, 95% CI 1.09–1.72, P = .008). CONCLUSIONS: Plasma ADM is a valuable biomarker to confirm COPD exacerbation; furthermore, plasma ADM independently predicts the need of ICU care, although it is not associated with long-term mortality in patients with COPD exacerbation.Keywords
This publication has 29 references indexed in Scilit:
- Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patientsInternational Journal of Cardiology, 2013
- Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoeaEuropean Heart Journal, 2012
- Chronic obstructive pulmonary diseaseThe Lancet, 2012
- Global and regional burden of disease and risk factors, 2001: systematic analysis of population health dataThe Lancet, 2006
- Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary diseaseRegulatory Peptides, 2005
- Adrenomedullin and adrenomedullin binding protein-1 downregulate TNF-α in macrophage cell line and rat Kupffer cellsRegulatory Peptides, 2003
- An investigation into the antimicrobial effects of adrenomedullin on members of the skin, oral, respiratory tract and gut microfloraFEMS Immunology & Medical Microbiology, 1999
- Increased plasma adrenomedullin in acute myocardial infarctionAmerican Heart Journal, 1996
- Hospital and 1-Year Survival of Patients Admitted to Intensive Care Units With Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseJAMA, 1995
- Adrenomedullin: A Novel Hypotensive Peptide Isolated from Human PheochromocytomaBiochemical and Biophysical Research Communications, 1993